FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

13 Observations in Zhejiang Hushai Inspection

[ Price : $8.95]

FDA releases the form FDA-483 with 13 observations from an April inspection at Chinas Zhejiang Hushai Pharmaceutical Co.

Active Drug Shortages Still Trending Up

[ Price : $8.95]

The American Society of Health System Pharmacists says there were 227 active drug shortages in the second quarter of 2026, trendin...

FDA Reevaluating Makarys Journal Articles, Podium Policies: DeGette

[ Price : $8.95]

Rep. Diana DeGette (D-CO) wins FDA assurances that several policy announcements issued during former commissioner Marty Makary's t...

Nihon Kohden Marketing Adulterated, Misbranded Devices: FDA

[ Price : $8.95]

FDA warns Irvine, CA-based Nihon Kohden Digital Health Solutions that it is marketing an adulterated and misbranded unapproved med...

Hearing Highlights Concerns Over Biomedical Innovation Growing in China

[ Price : $8.95]

Witnesses at a House Energy and Commerce Health Subcommittee hearing urge lawmakers to modernize the nation's clinical trial syste...

House Hearing Previews Debate Over FDA Modernization, User Fees

[ Price : $8.95]

House Energy and Commerce Health Subcommittee leaders reveal differing views over whether the Trump administration's policies are ...

A New Era of Innovation for FDA Public Health Pillars

[ Price : $8.95]

FDA acting commissioner Kyle Diamantas positions the agencys four public health pillars as a means to fulfill its enduring mission...

VAI Close Out for HLB Inspection

[ Price : $8.95]

A Cancer Network post says FDA issued a voluntary action indicated close-out letter to HLB following a CGMP inspection at a facili...

Kennedy Wanted Sentinel, BEST Data: Reuters

[ Price : $8.95]

A Reuters deep dive into HHS secretary Robert F. Kennedy Jr.s efforts to eliminate childhood vaccine requirements says his aides a...

Priority Review for Gazyva sBLA for Primary Membranous Nephropathy

[ Price : $8.95]

FDA grants Roche a priority review for its supplemental BLA seeking approval for Gazyva (obinutuzumab) for treating adults with pr...